Log in

ASX:AHZAdmedus Stock Price, Forecast & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Admedus Limited, a healthcare company, develops, commercializes, and distributes various medical technologies and devices. It manufactures, distributes, and sells proprietary ADAPT regenerative tissue products; and researches and develops regenerative medicine and immunotherapies. The company offers CardioCel, a bio-scaffold material to repair congenital heart deformities and other heart defects, as well as to reconstruct dysfunctional heart valves and valve leaflets; and CardioCel 3D that enables physicians access to an arch reconstruction solution with non-antigenic response and calcification resistance. It also provides VascuCel, a collagen scaffold used in cardiac repairs and reconstructions; ambIT infusion pumps for the delivery of medications and pain relief; arcomed infusion systems; and Eldor, a specialized fenestrated catheters for the infusion of local anesthetics into surgical sites for post-operative pain management. In addition, the company offers DOSI-FUSER, a portable elastomeric pump; and DOSI-PAIN, a wound catheter for postoperative continuous infusion. The company was formerly known as Allied Healthcare Group Limited and changed its name to Admedus Limited in November 2013. Admedus Limited is based in Toowong, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Phone61 7 3152 3200



Sales & Book Value

Annual Sales$17.08 million
Book ValueA$2.63 per share



Next Earnings DateN/A
OptionableNot Optionable

Receive AHZ News and Ratings via Email

Sign-up to receive the latest news and ratings for AHZ and its competitors with MarketBeat's FREE daily newsletter.

Admedus (ASX:AHZ) Frequently Asked Questions

Has Admedus been receiving favorable news coverage?

Media stories about AHZ stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Admedus earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutAdmedus.

Who are some of Admedus' key competitors?

Who are Admedus' key executives?

Admedus' management team includes the following people:
  • Mr. Wayne G. Paterson, CEO, Pres, MD & Exec. Director (Age 53)
  • Mr. Matthew McDonnell, Chief Financial Officer
  • Mr. David St. Denis, Chief Operating Officer
  • Ms. Martha Engel, Gen. Counsel
  • Dr. Kiran Bhirangi, Chief Medical Officer

What is Admedus' stock symbol?

Admedus trades on the ASX under the ticker symbol "AHZ."

How big of a company is Admedus?

Admedus has a market capitalization of $0.00 and generates $17.08 million in revenue each year.

What is Admedus' official website?

The official website for Admedus is www.admedus.com.

How can I contact Admedus?

The company can be reached via phone at 61 7 3152 3200.

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.